Differences between botulinum toxin types
Botulinum toxin serotypes share the same general therapeutic concept but differ in molecular targets, product development history, and clinical relevance. In current practice, the most important distinction is between type A and type B.
Key differences
Section titled “Key differences”| Topic | Type A | Type B |
|---|---|---|
| Current market role | Dominant | Specialized |
| Major product visibility | Very high | Limited |
| Aesthetic use | Extensive | Minimal |
| Therapeutic scope | Broad | Narrower |
| Representative brand node | Botox, Dysport, Xeomin | Myobloc / Neurobloc |
Why this matters
Section titled “Why this matters”Serotype differences affect how the market is organized. Most leading brands such as Botox, Dysport, Xeomin, and Nabota / Jeuveau are built around type A, while Myobloc / Neurobloc gives the site a concrete type B comparison point. That in turn shapes which companies become major manufacturers and which indications receive the deepest evidence base.
Clinical interpretation
Section titled “Clinical interpretation”The practical lesson is not that one serotype is universally better, but that each must be interpreted in the context of formulation, indication, treatment objective, and issues such as immunogenicity. That is why the encyclopedia maps toxin type pages to brand pages, company pages, and indication pages rather than treating serotypes in isolation.